Evidence map›Paper›PMID 32641237›Full record

ArticleGynecologic oncology2020

Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.

Katharine K Brieger, Siri Peterson, Alice W Lee, Bhramar Mukherjee, Kelly M Bakulski, Aliya Alimujiang, Hoda Anton-Culver, Michael S Anglesio, Elisa V Bandera, Andrew Berchuck and 42 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Reproductive Factors Do Not Influence Survival with Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  13. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  14. Article
  15. Article
  16. Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model.American journal of translational research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Katharine K BriegerDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Siri PetersonDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Alice W LeeDepartment of Public Health, California State University Fullerton, Fullerton, CA, USA.
Bhramar MukherjeeDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Kelly M BakulskiDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Aliya AlimujiangDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Hoda Anton-CulverDepartment of Medicine, University of California Irvine, Irvine, CA, USA.
Michael S AnglesioDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Andrew BerchuckDivision of Gynecologic Oncology, Duke University School of Medicine, Durham, NC, USA.
David D L BowtellPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.
Georgia Chenevix-TrenchDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Kathleen R ChoDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Daniel W CramerDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Anna DeFazioCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia.
Jennifer A DohertyHuntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Dale W GarsedPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.
Simon A GaytherCedars Sinai Medical Center, Los Angeles, CA, USA.
Aleksandra Gentry-MaharajMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
Ellen L GoodeDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Marc T GoodmanSamuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Holly R HarrisProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Estrid HøgdallDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
David G HuntsmanDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada.
Hui ShenVan Andel Research Institute (VARI), Grand Rapids, MI, USA.
Allan JensenDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Sharon E JohnattyDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Susan J JordanUniversity of Queensland, School of Public Health, Brisbane, Australia; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Susanne K KjaerDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Jolanta KupryjanczykDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Diether LambrechtsVesalius Research Center, VIB, Leuven, Belgium; Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium.
Karen McLeanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, USA.
Usha MenonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.
Francesmary ModugnoWomens Cancer Research Center, Magee-Women's Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, USA.
Kirsten MoysichDivision of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Roberta NessSchool of Public Health, University of Texas Health Science Center at Houston (UTHealth), TX, USA.
Susan J RamusSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Jean RichardsonAdult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney. Sydney, New South Wales, Australia.
Harvey RischChronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Britton TrabertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Argyrios ZiogasDepartment of Medicine, University of California Irvine, Irvine, CA, USA.
Kathryn L TerryDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Gillian E HanleyDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
Paul PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Penelope M WebbUniversity of Queensland, School of Public Health, Brisbane, Australia; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Gynaecological Cancers Group, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, QLD 4006, Australia.
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Celeste Leigh PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. Electronic address: lpearce@umich.edu.
Ovarian Cancer Association Consortium

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6M
USC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DEAPEN, DENNIS M. · 1985 to 2009
$18.2M
University of Michigan Training Program in Genomic ScienceT32HG000040 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sebastian Zoellner · 1995 to 2026
$16.4M
Novel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3M
Cancer Research UK 10119Cancer Research UK 16561Medical Research Council MC_UU_12023/20NCI NIH HHS K07 CA080668NCI NIH HHS K07 CA095666NCI NIH HHS K22 CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA072720NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA080742NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCRR NIH HHS M01 RR000056NHGRI NIH HHS T32 HG000040NIGMS NIH HHS T32 GM007863
6 · The paper itself

Abstract

purposePrior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.

methodsData from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.

resultsUse of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival.

conclusionsPre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.

Indexed as

AgedEstrogen Replacement TherapyFemaleHormone Replacement TherapyHumansMiddle AgedNeoplasm, ResidualNeoplasm StagingOvarian NeoplasmsPostmenopauseProgestinsProgression-Free SurvivalProportional Hazards ModelsSurvival RateProgestins

Identifiers

PMID32641237
PMCPMC7487048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.